Dihydroartemisinin disrupts the malaria parasite's membrane structures, leading to its self-destruction. It also inhibits protein and nucleic acid synthesis.
First-trimester pregnancy, hypersensitivity to its components, history of cardiac arrhythmias or bradycardia, and concurrent use of QTc-prolonging medications.
1.5 tablets per day for three days (4.5 tablets total).
Nausea, vomiting, reduced reticulocyte counts, dizziness, vertigo, headache, abdominal discomfort, leucopenia, dyspnea, and palpitations.
Dihydroartemisinin is rapidly absorbed, reaching peak concentration in 1 hour, with a half-life of 4 hours. It's excreted in urine and feces. Piperaquine Phosphate is 80-90% absorbed within 24 hours, with a half-life of 20-22 days. It's eliminated through bile.
Treatment of malaria caused by P. falciparum, P. vivax, and P. malariae.
Avoid during the first trimester if possible. Do not breastfeed during treatment.
Symptomatic and supportive therapy, including ECG monitoring.
In light-resistant containers below 30°C, out of reach of children.
40 mg Dihydroartemisinin, 320 mg Piperaquine Phosphate, and excipients.
Interferes with the malaria parasite's food vacuole membrane, leading to its autophagocytosis.
Blister packs of 6, 9, 12, and 15 tablets within a carton, with a patient information leaflet.